1. Home
  2. ANAB vs AFYA Comparison

ANAB vs AFYA Comparison

Compare ANAB & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$55.75

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Afya Limited

AFYA

Afya Limited

HOLD

Current Price

$14.82

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
AFYA
Founded
2005
1999
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ANAB
AFYA
Price
$55.75
$14.82
Analyst Decision
Buy
Hold
Analyst Count
11
5
Target Price
$74.64
$17.00
AVG Volume (30 Days)
587.2K
99.8K
Earning Date
03-03-2026
03-12-2026
Dividend Yield
N/A
4.44%
EPS Growth
91.02
N/A
EPS
N/A
N/A
Revenue
$234,603,000.00
N/A
Revenue This Year
N/A
$10.11
Revenue Next Year
$33.49
$7.57
P/E Ratio
N/A
$9.30
Revenue Growth
157.01
N/A
52 Week Low
$15.40
$13.00
52 Week High
$68.39
$19.76

Technical Indicators

Market Signals
Indicator
ANAB
AFYA
Relative Strength Index (RSI) 42.55 55.89
Support Level $52.68 $14.16
Resistance Level $57.70 $15.50
Average True Range (ATR) 4.06 0.65
MACD -1.35 0.07
Stochastic Oscillator 8.37 65.14

Price Performance

Historical Comparison
ANAB
AFYA

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

Share on Social Networks: